Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma
Phase 2 hypofractionation study usion proton beam therapy for prostate adenocarcinoma
Prostate Adenocarcinoma
RADIATION: proton beam therapy
clinical outcomes, To evaluate biochemical failure-free survival (BCFFS), up to 5years from a initial follow-up
acute toxicity, to evaluate acute toxicities by CTCAE version 3.0, up to 5years from a initial follow-up|late toxicity, to evaluated late toxicities by CTCAE version 3.0, up to 5years from a initial follow-up|overall survival, to evaluated overall survival, up to 5years from a initial follow-up
Phase 2 hypofractionation study usion proton beam therapy for prostate adenocarcinoma